Rein Therapeutics Inc Asset Resilience Ratio
Rein Therapeutics Inc asset resilience ratio. Rein Therapeutics Inc (RNTX) has an Asset Resilience Ratio of 48.66% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Rein Therapeutics Inc (RNTX) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Rein Therapeutics Inc (2017–2023)
Asset resilience ratio of Rein Therapeutics Inc from 2017 to 2023. This chart shows how Rein Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Rein Therapeutics Inc total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Rein Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Rein Therapeutics Inc asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $32.10 Million | 48.66% |
| Total Liquid Assets | $32.10 Million | 48.66% |
Asset Resilience Insights
- Very High Liquidity: Rein Therapeutics Inc maintains exceptional liquid asset reserves at 48.66% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rein Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Rein Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Rein Therapeutics Inc Asset Resilience Ratio by Year (2017–2023)
Rein Therapeutics Inc asset resilience ratio by year from 2017 to 2023. The table below shows the annual Asset Resilience Ratio data for Rein Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $106.01 Million | -- |
| 2022-12-31 | 72.92% | $16.05 Million | $22.01 Million | -14.40pp |
| 2021-12-31 | 87.32% | $42.33 Million | $48.48 Million | +45.96pp |
| 2020-12-31 | 41.36% | $6.76 Million | $16.34 Million | -7.62pp |
| 2019-12-31 | 48.98% | $12.97 Million | $26.47 Million | +15.79pp |
| 2018-12-31 | 33.19% | $10.06 Million | $30.31 Million | -40.62pp |
| 2017-12-31 | 73.81% | $38.89 Million | $52.69 Million | -- |
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b a… Read more